We found the comments by Dr van der Sluijs-Gelling et al regarding the immunophenotypic modulation observed in 24 childhood B-cell precursor ALL patients at days 15 and 28 of DCOG-9 treatment protocol quite interesting. 1 These data confirm our recent results obtained in a similar series of children treated according to the AIEOP-BFM ALL2000 protocol. 2 In order to investigate the mechanism of immunophenotypic modulation, van der Sluijs-Gelling et al cultured leukemic blasts from five patients for 96 h in the presence of different drugs, including prednisolone. They observed a comparable expression pattern between leukemic cells exposed to cytotoxic agents in vitro and residual blasts present at day 15 of treatment in the same patient. To further demonstrate the relation between cell kill and modulation, these authors stained leukemic cells from one patient with a cocktail of monoclonal antibodies as well as with 7-AAD, observing modulation only in dead cells, while viable leukemic cells retained their original immunophenotype. They conclude that the immunophenotypic modulation can be reproduced in vitro and that this phenomenon is caused by drug-induced cell death, which results in loss of membrane antigen (downmodulation) and higher aspecific staining (upmodulation). We do not fully agree with the reported conclusions; in fact, in our study, we distinguished viable from dying and/or dead cells on the basis of the FSC/SSC distribution. 2 Although this method is not considered as accurate as 7-AAD staining, we found that the residual modulated leukemic cells always were located within the same, original FSC/SSC area as at diagnosis (Figure 1 ), and this observation was supported by statistical analysis, while apoptotic and dead cells (like dark-gray colored cells in Figure 2 2e, f of the van der Sluijs-Gelling's report) were systematically excluded. Although it is reasonable to suppose that a phenomenon observed in the presence of effective antileukemic drugs may be related to mechanisms resulting in cell death, the culture system used by van der Sluijs-Gelling and collaborators to demonstrate such a direct correlation could be limited by the presence of spontaneous apoptosis (these data are not reported for the control culture). In fact, it has been demonstrated that blasts of B-cell precursor ALL do not survive in vitro without the support of bone marrow-derived stroma layer, even for a short-term period of culture. 3 Thus, culture of B-cell precursor ALL cells for 96 h in standard conditions could imply the contemporary presence of different apoptotic signalling pathways, including those not related to drugs. We are also concluding the drug-induced immunophenotypic modulation in vitro study using a stroma-supported culture system, and our preliminary data indicate that this phenomenon can be reproduced in vitro even when excluding apoptotic cells. Nevertheless, we would like to maintain the conclusion of van Figure 1 Flow-cytometric analysis of light scatter and fluorescence characteristics. Expression of CD10 and CD34, measured at diagnosis (upper-right dot plot) and at day 15 (lower-right), in a representative case. Modulation of both antigens is observed during follow-up compared to diagnosis, but scattering characteristics (left dot plots) remain unchanged. Only leukemic cells are shown.
der ) families of cyclin-dependent kinase inhibitors (CKI). 1 The INK4 family of CKIs bind to and inhibit CDK 4/6 .
2 By contrast, the CKIs of the CIP/KIP family may bind to both CDK 2 and CDK 4/6 , and modulate their kinase activities. In quiescent cells, CIP/KIP CKIs bind to and inhibit the activity of CDK 2 , resulting in cell cycle arrest. In cycling cells, CKIs of the CIP/KIP Table 1 MSP: primer sequences and reaction conditions 
